Our mission


Our mission is to develop personalized solutions based on specific and innovative biomarkers for the diagnosis, the prognosis and the follow-up of musculoskeletal disorders

Founded in October 2010, as a spin-off of the Liège University in Belgium, ARTIALIS became a first-mover biotech company specialized in the development and the clinical application of biomarkers-based immunoassays and trials.

ARTIALIS capitalizes on innovation, dynamism, creativity, and ethics to become a leader of the joint health market.